We are live on ! Find out more
LFCR icon

Lifecore Biomedical
LFCR

86 hedge funds and large institutions have $220M invested in Lifecore Biomedical in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 28 increasing their positions, 32 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

2.16% less ownership

Funds ownership: 85.76% → 83.6% (-2.2%)

4% less funds holding

Funds holding: 90 → 86 (-4)

13% less repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 32

13% less capital invested

Capital invested by funds: $252M → $220M (-$32.1M)

57% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 7

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $71K

Holders
86
Holders Change
-4
Holders Change %
-4.44%
% of All Funds
1.48%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
3
Increased
28
Reduced
32
Closed
7
Calls
–
Puts
$71K
Net Calls
-$71K
Net Calls Change
-$76K

Top Buyers

Rank Fund Capital Flow
1
2L
22NW LP
Washington
+$4.2M
2
PAIM
Punch & Associates Investment Management
Minnesota
+$3.38M
3
PHP
Parkman Healthcare Partners
Connecticut
+$820K
4
Boston Partners
Boston Partners
Massachusetts
+$161K
5
GCP
GSA Capital Partners
United Kingdom
+$157K

Top Sellers

Rank Fund Capital Flow
1
ICM
ISZO Capital Management
New York
-$7.23M
2
ERSOT
Employees Retirement System of Texas
Texas
-$1.7M
3
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$1.09M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$994K
5
BlackRock
BlackRock
New York
-$964K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$952K +$102K +9,992 +10%
N
27
Nuveen
North Carolina
$924K -$5.1K -502 -0.5%
DC
28
Defender Capital
North Carolina
$769K -$50.8K -5,000 -5%
OAM
29
Oppenheimer Asset Management
New York
$728K -$7.16K -704 -0.9%
Goldman Sachs
30
Goldman Sachs
New York
$728K +$31.9K +3,139 +4%
GI
31
GAMCO Investors
Connecticut
$702K +$20.3K +2,000 +3%
RA
32
Royce & Associates
New York
$672K – – –
AA
33
Ancora Advisors
Ohio
$628K – – –
Charles Schwab
34
Charles Schwab
California
$605K +$10 +1 +0%
Invesco
35
Invesco
Georgia
$574K -$78.1K -7,679 -11%
BCM
36
Bridgeway Capital Management
Texas
$489K -$254K -25,000 -31%
LCM
37
Lewis Capital Management
California
$425K +$89.3K +8,780 +23%
D.E. Shaw & Co
38
D.E. Shaw & Co
New York
$413K -$41.3K -4,065 -8%
RhumbLine Advisers
39
RhumbLine Advisers
Massachusetts
$362K +$28.7K +2,820 +7%
DT
40
Diversified Trust
Tennessee
$325K – – –
TRCT
41
Tower Research Capital (TRC)
New York
$277K -$4.2K -413 -1%
CCB
42
Cutter & Co Brokerage
Missouri
$253K – – –
KA
43
Keene & Associates
Texas
$233K – – –
MAM
44
Martingale Asset Management
Massachusetts
$218K – – –
UBS Group
45
UBS Group
Switzerland
$204K -$2K -197 -0.9%
State Board of Administration of Florida Retirement System
46
State Board of Administration of Florida Retirement System
Florida
$192K – – –
Millennium Management
47
Millennium Management
New York
$184K +$325 +32 +0.2%
RP
48
Riverwater Partners
Wisconsin
$183K -$126K -12,349 -38%
AllianceBernstein
49
AllianceBernstein
Tennessee
$166K +$6.1K +600 +3%
SG Americas Securities
50
SG Americas Securities
New York
$163K -$4.45K -438 -2%
1
2
3 4

LFCR Hedge Fund Activity: Q3 2022 in Review

86 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q3 2022, worth a combined $220M — down 13% from $252M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of LFCR and 3 opened new positions — a net loss of 4 holders — while 32 trimmed existing stakes and 28 added.

The largest buyer was 22NW LP, adding an estimated $4.2M. The largest seller was ISZO Capital Management, cutting an estimated $7.23M.

  • 86 institutional investors held Lifecore Biomedical (LFCR) as of Q3 2022, down from 90 in Q2 2022.
  • Funds reported $220M of Lifecore Biomedical stock for Q3 2022, down 13% quarter-over-quarter.
  • 3 funds opened new Lifecore Biomedical positions in Q3 2022 and 7 closed out, a net change of -4 holders.
  • The largest Lifecore Biomedical buyer in Q3 2022 was 22NW LP, an estimated $4.2M added.
  • The largest Lifecore Biomedical seller in Q3 2022 was ISZO Capital Management, an estimated $7.23M sold.

Based on aggregated 13F filings for Q3 2022.